Education
About Us
Working with TipRanks
Follow Us
Celcuity (CELC)
NASDAQ:CELC
CELC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.58 - $63.06
Previous CloseN/A
Volume14.25K
Average Volume (3M)911.81K
Market Cap
$2.29B
Enterprise Value$513.93M
Total Cash (Recent Filing)$205.69M
Total Debt (Recent Filing)$98.71M
Price to Earnings (P/E)―
Beta0.28
Next Earnings
Nov 17, 2025EPS Estimate
-1.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding42,426,712
10 Day Avg. Volume884,353
30 Day Avg. Volume911,806
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.22
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-16.52K
Enterprise Value/Ebitda-4.38
Forecast
1Y Price Target
$76.33Price Target Upside50.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessCelcuity reported positive topline results from the PIK3CA WT portion of the Phase 3 VIKTORIA-1 trial testing their pan-PI3K/mTOR inhibitor, gedatolisib, for ER+ breast cancer patients.
Financial FlexibilityThe latest amendment increases the total term loan facility size up to $500 million, significantly enhancing the company's financial strength.
Regulatory ProgressThe FDA agreed to accept the NDA for Celcuity's pan-PI3K/mTOR inhibitor, gedatolisib, under the agency's Real-Time Oncology Review program.
Bears Say
Market SentimentShort Interest (% Float) is at 23.9%.
Celcuity News
CELC FAQ
What was Celcuity’s price range in the past 12 months?
Celcuity lowest stock price was $7.58 and its highest was $63.06 in the past 12 months.
What is Celcuity’s market cap?
Celcuity’s market cap is $2.29B.
When is Celcuity’s upcoming earnings report date?
Celcuity’s upcoming earnings report date is Nov 17, 2025 which is in 51 days.
How were Celcuity’s earnings last quarter?
Celcuity released its earnings results on Aug 14, 2025. The company reported -$1.04 earnings per share for the quarter, missing the consensus estimate of -$0.884 by -$0.156.
Is Celcuity overvalued?
According to Wall Street analysts Celcuity’s price is currently Undervalued.
Does Celcuity pay dividends?
Celcuity does not currently pay dividends.
What is Celcuity’s EPS estimate?
Celcuity’s EPS estimate is -1.02.
How many shares outstanding does Celcuity have?
Celcuity has 42,426,712 shares outstanding.
What happened to Celcuity’s price movement after its last earnings report?
Celcuity reported an EPS of -$1.04 in its last earnings report, missing expectations of -$0.884. Following the earnings report the stock price went down -0.193%.
Which hedge fund is a major shareholder of Celcuity?
Currently, no hedge funds are holding shares in CELC
Celcuity Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$76.33 (50.85% Upside)
$76.33 (50.85% Upside)
Blogger Sentiment
Bullish
CELC Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 439.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $10.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 48.2%
Last 30 Days ▲ 48.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
255.33%
12-Months-Change
Fundamentals
Return on Equity
-134.54%
Trailing 12-Months
Asset Growth
-37.24%
Trailing 12-Months
Company Description
Celcuity
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
CELC Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a strong set of highlights with significant clinical trial progress, patent extension, and financial fortification, although it was balanced by increased losses and expenses.View all CELC earnings summariesCELC Stock 12 Month Forecast
Average Price Target
$76.33
▲(50.85% Upside)
Technical Analysis
Cidara Therapeutics
―
IDEAYA Biosciences
―
Tarsus Pharmaceuticals
―
Belite Bio, Inc. ADR
―
Apogee Therapeutics
―
Ownership Overview
10.69% Insiders
11.13% Mutual Funds
50.67% Other Institutional Investors
20.39% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---